Marilyn Glassberg Csete, MD
Pulmonary Disease, Internal Medicine
Speaks
Languages
Spanish
French
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888
Appointments (New Patients Welcome)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888Services & Specialties
Areas of Specialization
- Internal Medicine
- Pulmonary Disease
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood
, IL 60153
About
Academic Title
Professor
Ages Seen
Additional Resources
Education & Certifications
Education
Education:
University of Miami Miller School of Medicine
(1985)
Education:
University of Miami Miller School of Medicine
(1985)
Internship:
University of Miami Hospital & Clinics
(1986)
Residency:
University of Miami Hospital & Clinics
(1988)
Fellowship:
University of Miami Hospital & Clinics
(1991)
Fellowship:
University of Miami Hospital
(1992)
Fellowship:
University of Miami Hospital & Clinics
(1992)
Board Certifications
Pulmonary Disease, Pulmonary Disease, American Board of Internal Medicine Subspecialty (1994)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- Ratio of miRNA-29 to miRNA-199 expression coordinates mesenchymal stem cell repair of bleomycin-induced pulmonary injury. Elliot, S. J.; Anderson-Terhune, D.; Roos, B.; Rubio, G. A.; Xia, X.; Pereira-Simon, S.; Catanuto, P.; Civettini, G.; Hagen, E. S.; Arvanitis, C.; Shahzeidi, S.; Glassberg, M. K.; Molecular therapy. Nucleic acids
- Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease. Johannson, K. A.; Adegunsoye, A.; Behr, J.; Cottin, V.; Glanville, A. R.; Glassberg, M. K.; Goobie, G. C.; Jenkins, R. G.; Kim, J. S.; Lee, C. T.; Redlich, C. A.; Richeldi, L.; Salisbury, M. L.; Tetley, T.; Corte, T. J.; American journal of respiratory and critical care medicine
- Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Corte, T. J.; Behr, J.; Cottin, V.; Glassberg, M. K.; Kreuter, M.; Martinez, F. J.; Ogura, T.; Suda, T.; Wijsenbeek, M.; Berkowitz, E.; Elpers, B.; Kim, S.; Watanabe, H.; Fischer, A.; Maher, T. M.; American journal of respiratory and critical care medicine
- Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial. Nathan, S. D.; Rajicic, N.; Dudenhofer, R.; Hussain, R.; Argula, R.; Bandyopadhyay, D.; Luckhardt, T.; Muehlemann, N.; Flaherty, K. R.; Glassberg, M. K.; Lancaster, L.; Raghu, G.; Fernandes, P.; Annals of the American Thoracic Society
- Inflammation unites diverse acute and chronic diseases. Libby, P.; Smith, R.; Rubin, E. J.; Glassberg, M. K.; Farkouh, M. E.; Rosenson, R. S.; European journal of clinical investigation
- The Controversy Continues: Whether to Perform Plasma Exchange, and with What Dose of Steroids, in the PEXIVAS Trial. Glassberg, M. K.; Ali, A.; Gregorini, G.; American journal of respiratory and critical care medicine
- Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. Adegunsoye, A.; Kropski, J. A.; Behr, J.; Blackwell, T. S.; Corte, T. J.; Cottin, V.; Glanville, A. R.; Glassberg, M. K.; Griese, M.; Hunninghake, G. M.; Johannson, K. A.; Keane, M. P.; Kim, J. S.; Kolb, M.; Maher, T. M.; Oldham, J. M.; Podolanczuk, A. J.; Rosas, I. O.; Martinez, F. J.; Noth, I.; Schwartz, D. A.; American journal of respiratory and critical care medicine
- Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Raghu, G.; Ghazipura, M.; Fleming, T. R.; Aronson, K. I.; Behr, J.; Brown, K. K.; Flaherty, K. R.; Kazerooni, E. A.; Maher, T. M.; Richeldi, L.; Lasky, J. A.; Swigris, J. J.; Busch, R.; Garrard, L.; Ahn, D. H.; Li, J.; Puthawala, K.; Rodal, G.; Seymour, S.; Weir, N.; Danoff, S. K.; Ettinger, N.; Goldin, J.; Glassberg, M. K.; Kawano-Dourado, L.; Khalil, N.; Lancaster, L.; Lynch, D. A.; Mageto, Y.; Noth, I.; Shore, J. E.; Wijsenbeek, M.; Brown, R.; Grogan, D.; Ivey, D.; Golinska, P.; Karimi-Shah, B.; Martinez, F. J.; American journal of respiratory and critical care medicine
- Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. Behr, J.; Nathan, S. D.; Costabel, U.; Albera, C.; Wuyts, W. A.; Glassberg, M. K.; Haller, H.; Alvaro, G.; Gilberg, F.; Samara, K.; Lancaster, L.; Advances in therapy
- Urine-derived exosomes from individuals with IPF carry pro-fibrotic cargo. Elliot, S.; Catanuto, P.; Pereira-Simon, S.; Xia, X.; Shahzeidi, S.; Roberts, E.; Ludlow, J.; Hamdan, S.; Daunert, S.; Parra, J.; Stone, R.; Pastar, I.; Tomic-Canic, M.; Glassberg, M. K.; eLife